SCHEMBL10268552

SCHEMBL10268552

COc1ccc(C(N)=O)cc1NC(=O)c1cc(-c2cc3ccccc3s2)c2[nH]ncc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
MAPKAPK2 P49137 8/20 0.43
TNFRSF1A P19438 1/20 0.43
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
AURKA O14965 1/20 0.42
MAPK13 O15264 1/20 0.42
PDPK1 O15530 1/20 0.42
DAPK3 O43293 1/20 0.42
DYRK3 O43781 1/20 0.42
ROCK2 O75116 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
ERBB2 P04626 1/20 0.42
PRKCG P05129 1/20 0.42
CDK1 P06493 1/20 0.42
MET P08581 1/20 0.42
PIM1 P11309 1/20 0.42
PHKG2 P15735 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10269192 0.92 KDR (0.42) MAPKAPK2TNFRSF1ACDC7PLK4AURKA
SCHEMBL10269655 0.90 MEN1 (0.51) MAPKAPK2MAPTTP53RXFP1SMN1; SMN2
SCHEMBL10269330 0.90 NPC1 (0.47) MAPKAPK2CDC7PLK4AURKAMAPK13
SCHEMBL10269032 0.88 MAPT (0.47) MAPKAPK2MAPTTP53RXFP1SMN1; SMN2
SCHEMBL10269338 0.88 MEN1 (0.48) MAPKAPK2TNFRSF1ACDC7PLK4AURKA
SCHEMBL10269034 0.88 ALDH1A1 (0.55) MAPKAPK2KDRMAPTTP53RXFP1
SCHEMBL10269041 0.83 KDR (0.43) MAPKAPK2CDC7PLK4AURKAMAPK13
SCHEMBL10269603 0.83 HPSE (0.53) CYP1A2AURKACDK1CDK2AURKB
SCHEMBL10213041 0.83 MAPKAPK2 (0.49) MAPKAPK2CDC7PLK4AURKAMAPK13
SCHEMBL10269332 0.82 TP53 (0.59) MAPTTP53RXFP1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 CYP1A2 15/4885MAPKAPK2 1905/4885TNFRSF1A 4811/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 CYP1A2 15/4885MAPKAPK2 1905/4885TNFRSF1A 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.